Finding the sweet spot for metformin in 18F-FDG-PET
The effect of oral hypoglycemic agents on fluorine-18-flurodeoxyglucose (18F-FDG) uptake is less understood than the effect of exogenous insulin. In this study, the effect of withholding metformin on 18F-FDG distribution in subsequent PET imaging was evaluated.Patients and methods
A retrospective observational study was carried out. A total of 15 patients taking metformin were grouped according to the time interval from the last dose of metformin to 18F-FDG-PET. Those who received PET after stopping metformin for less than 24 h were compared with those stopping metformin 24–48 h before PET. The 18F-FDG uptake and PET image fidelity for these groups were compared qualitatively and the associated blood glucose was recorded. The average standardized uptake value of the liver, tongue, and subcutaneous tissues among the groups were also compared.Results
The 18F-FDG-PET distribution and image quality were found to be the best at time points greater than 24 h following metformin dose. There was significantly increased 18F-FDG uptake in the liver and tongue and tongue-to-liver ratio in patients who had metformin within 24 h of 18F-FDG-PET compared with those who last had metformin greater than 24 h before 18F-FDG-PET; however, the 18F-FDG uptake in the subcutaneous tissues was unchanged.Conclusion
Less than 24 h between metformin dose and 18F-FDG-PET resulted in increased muscle and fat uptake in addition to increased bowel uptake. Abnormal 18F-FDG uptake can limit the diagnostic quality of an exam and affect 18F-FDG uptake in cancer. The emerging role of biguanides in the treatment of cancer calls for more personalized standardization for 18F-FDG-PET in the presence of oral hypoglycemic agents.